Literature DB >> 21530171

A framework for applying unfamiliar trial designs in studies of rare diseases.

Samir Gupta1, Marie E Faughnan, George A Tomlinson, Ahmed M Bayoumi.   

Abstract

OBJECTIVE: Rare diseases may be difficult to study through conventional research methods, but are amenable to study through certain uncommonly used designs. We sought to explain these designs and to provide a framework to assist researchers in identifying the most appropriate design for a given research question. STUDY DESIGN AND
SETTING: We systematically searched for literature describing rare disease research frameworks, trial designs, and trials that applied them. We present the advantages and disadvantages of each approach using these published examples, and a practical framework to help researchers in selecting between design choices.
RESULTS: When research participants are limited, researchers should consider using: 1) a crossover design; 2) n-of-1 trials; or 3) one of the following adaptive designs: a) a response-adaptive randomization design, b) a ranking and selection design, c) an internal pilot design,or d) a sequential design. Bayesian analysis may be applied to conventional designs, or to any of these uncommon designs. Several of these approaches may also be used in combination. The choice between methods should be guided by factors related to the intervention, disease,anticipated recruitment duration and success, and current state of knowledge about the treatment.
CONCLUSION: These techniques may facilitate research in rare diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21530171     DOI: 10.1016/j.jclinepi.2010.12.019

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  36 in total

1.  Development and use of new therapeutics for rare diseases: views from patients, caregivers, and advocates.

Authors:  Aaron S Kesselheim; Sarah McGraw; Lauren Thompson; Kelly O'Keefe; Joshua J Gagne
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

2.  Performance of matching methods in studies of rare diseases: a simulation study.

Authors:  Irena Cenzer; W John Boscardin; Karin Berger
Journal:  Intractable Rare Dis Res       Date:  2020-05

3.  Cognitive-behavioural therapy targeting fear of progression in an interdisciplinary care program: a case study in systemic sclerosis.

Authors:  Linda Kwakkenbos; Linda M Willems; Frank H J van den Hoogen; Wim G J M van Lankveld; Hanneke Beenackers; Toon F van Helmond; Eni S Becker; Cornelia H M van den Ende
Journal:  J Clin Psychol Med Settings       Date:  2014-12

Review 4.  [Orphan drugs : New opportunities for the treatment of rare diseases].

Authors:  M Beck
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

5.  Patient-centeredness in the design of clinical trials.

Authors:  C Daniel Mullins; Joseph Vandigo; Zhiyuan Zheng; Paul Wicks
Journal:  Value Health       Date:  2014-05-05       Impact factor: 5.725

6.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10

7.  Principles of Good Clinical Trial Design.

Authors:  Ming-Wen An; Quyen Duong; Jennifer Le-Rademacher; Sumithra J Mandrekar
Journal:  J Thorac Oncol       Date:  2020-05-15       Impact factor: 15.609

Review 8.  Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?

Authors:  Beth K Potter; Sara D Khangura; Kylie Tingley; Pranesh Chakraborty; Julian Little
Journal:  Genet Med       Date:  2015-04-09       Impact factor: 8.822

9.  Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.

Authors:  Lisa V Hampson; John Whitehead; Despina Eleftheriou; Catrin Tudur-Smith; Rachel Jones; David Jayne; Helen Hickey; Michael W Beresford; Claudia Bracaglia; Afonso Caldas; Rolando Cimaz; Joke Dehoorne; Pavla Dolezalova; Mark Friswell; Marija Jelusic; Stephen D Marks; Neil Martin; Anne-Marie McMahon; Joachim Peitz; Annet van Royen-Kerkhof; Oguz Soylemezoglu; Paul A Brogan
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

Review 10.  Experimental designs for small randomised clinical trials: an algorithm for choice.

Authors:  Catherine Cornu; Behrouz Kassai; Roland Fisch; Catherine Chiron; Corinne Alberti; Renzo Guerrini; Anna Rosati; Gerard Pons; Harm Tiddens; Sylvie Chabaud; Daan Caudri; Clément Ballot; Polina Kurbatova; Anne-Charlotte Castellan; Agathe Bajard; Patrice Nony; Leon Aarons; Agathe Bajard; Clément Ballot; Yves Bertrand; Frank Bretz; Daan Caudri; Charlotte Castellan; Sylvie Chabaud; Catherine Cornu; Frank Dufour; Cornelia Dunger-Baldauf; Jean-Marc Dupont; Roland Fisch; Renzo Guerrini; Vincent Jullien; Behrouz Kassaï; Patrice Nony; Kayode Ogungbenro; David Pérol; Gérard Pons; Harm Tiddens; Anna Rosati; Corinne Alberti; Catherine Chiron; Polina Kurbatova; Rima Nabbout
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.